Sign up for our biotech newsletter to keep up with the latest in the science and politics driving the biotech industry. Sorry for the delay in getting this newsletter to you today – technical issues, you know how it goes. But fear not, we still have all the news you need to know!
Novo Nordisk is teaming up with telehealth providers to promote their GLP-1 drug, Wegovy, at a discounted price. This marketing strategy has raised concerns about potential overprescribing of drugs, as patients may be swayed by these deals. Legislators and health experts are keeping a close eye on these pharma and telehealth partnerships.
GSK’s Nucala has received FDA approval for COPD, setting up competition with Dupixent. Nucala has already shown promising results in clinical trials, reducing exacerbations and hospital visits. On the other hand, Merus has reported positive survival data for their drug in combination with Keytruda for head and neck cancer patients, with further studies underway to confirm these results.
The FDA has recommended new strains for Covid vaccines, with some drama surrounding the decision-making process. Questions have been raised about how these changes will align with a new framework for Covid vaccines proposed by FDA officials earlier this week. Stay tuned for more updates on the evolving landscape of biotech.
Not really sure why this matters, but it seems like the biotech industry is heating up with new developments and competition between drug companies. Maybe it’s just me, but it feels like there’s a lot at stake in these partnerships and approvals. Keep an eye on the FDA and upcoming clinical trials for more insights into the future of biotech.
And that’s a wrap for this edition of our biotech newsletter. Stay tuned for more updates and sign up to never miss a beat in the world of biotech.
